Localized large cell lymphoma: is there any need for radiation therapy?
- 1 September 2009
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Oncology
- Vol. 21 (5), 401-406
- https://doi.org/10.1097/cco.0b013e32832f3c8b
Abstract
Diffuse large B-cell lymphoma is the most common lymphoma diagnosed in the United States and presents as localized disease in about 25% of the patients. The standard of care was established by Southwest Oncology Group trial 8736, which showed the superiority of a short course of chemotherapy followed by radiation over a longer course of chemotherapy alone. This review discusses the studies that followed with the intent to establish whether the standard of care has changed. Subsequent studies examined the role of radiation therapy, the number of cycles and intensity of chemotherapy, and addition of rituximab. Interpretation of results has been confounded by patient selection, especially by including patients with bulky stage II disease. Quality of radiation therapy may have diminished its efficacy in some of the studies. Concurrent administration of rituximab provided a more modest improvement as compared with advanced disease setting. Attempts are now made to use PET scans to eliminate the need for radiation therapy in some patients. Radiation therapy remains useful when administered expediently and as initially described, but PET scans successfully define a subset of patients who do not benefit from radiation. Using a longer or more intensive course of rituximab-containing chemotherapy without radiation has never been compared to combined modality treatment and remains investigational.Keywords
This publication has 17 references indexed in Scilit:
- Phase II Study of Rituximab Plus Three Cycles of CHOP and Involved-Field Radiotherapy for Patients With Limited-Stage Aggressive B-Cell Lymphoma: Southwest Oncology Group Study 0014Journal of Clinical Oncology, 2008
- CHOP Alone Compared With CHOP Plus Radiotherapy for Localized Aggressive Lymphoma in Elderly Patients: A Study by the Groupe d’Etude des Lymphomes de l’AdulteJournal of Clinical Oncology, 2007
- Diffuse Aggressive Histologies of Non-Hodgkin Lymphoma: Treatment and Biology of Limited DiseaseSeminars in Hematology, 2006
- ACVBP versus CHOP plus Radiotherapy for Localized Aggressive LymphomaNew England Journal of Medicine, 2005
- Chemotherapy With or Without Radiotherapy in Limited-Stage Diffuse Aggressive Non-Hodgkin's Lymphoma: Eastern Cooperative Oncology Group Study 1484Journal of Clinical Oncology, 2004
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002
- Brief Chemotherapy and Involved-Region Irradiation for Limited-Stage Diffuse Large-Cell Lymphoma: An 18-Year Experience From the British Columbia Cancer AgencyJournal of Clinical Oncology, 2002
- Human natural killer cells with polyclonal lectin and immunoglobulinlike receptors develop from single hematopoietic stem cells with preferential expression of NKG2A and KIR2DL2/L3/S2Blood, 2001
- New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project.Journal of Clinical Oncology, 1998
- Chemotherapy Alone Compared with Chemotherapy plus Radiotherapy for Localized Intermediate- and High-Grade Non-Hodgkin's LymphomaNew England Journal of Medicine, 1998